
ResMed: GLP-1 Threats Are Overstated
Track RMD's AI-powered predictions, market trends, and investment insights.
You don't hold RMD in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedWith EPS at 10.37 and a PE ratio of 18.55, ResMed appears reasonably valued relative to its earnings power, suggesting solid underlying profitability. The valuation multiple is not stretched for a profitable, established med‑tech name, implying the market is pricing in moderate but sustainable growth rather than aggressive expectations. Overall, the earnings profile and multiple support a constructive view on fundamentals despite recent share price weakness.
The stock at $192.39 trades materially below its 200‑day moving average of $244.72, signaling a clear intermediate‑term downtrend. A 4.7% decline over the last month reinforces negative momentum, and trading this far under the 200‑day average typically reflects ongoing technical pressure. While the valuation is not demanding, the current technical setup leans bearish in the near to medium term.
Alternative data for ResMed presents a mixed but generally stable picture: web traffic is sizable, and social media followings are mostly growing modestly, while job openings have declined 16.6% month over month. The reduction in job postings could signal a more cautious hiring stance or efficiency focus, whereas steady to rising social audiences suggest ongoing brand engagement. Overall, these signals neither strongly reinforce the bearish technicals nor fully offset them, pointing to a neutral read‑through.
ResMed’s fundamentals, as implied by its earnings and valuation, look solid and reasonably priced, but the stock is in a clear technical downtrend, trading well below its 200‑day moving average with recent negative momentum. Alternative data are mixed: hiring has slowed, yet digital and social engagement remain broadly stable to positive. Taken together, the setup appears neutral overall—fundamentals offer support, but technical weakness and cautious hiring temper a fully bullish stance.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
ResMed (RMD) is currently trading at $186.44 on the NYSE, carrying a market capitalization of approximately $27.0 billion. The stock logged a 2.2% decline in the most recent session on volume of over 2.4 million shares, signaling notable selling pressure. As a dominant player in the Medical Instruments and Supplies sector, ResMed operates across its Sleep and Respiratory Care segment alongside a growing Software as a Service division. This dual-segment structure positions the company at the intersection of hardware-driven healthcare and recurring cloud-based revenue — a profile that attracts both growth and value-oriented investors.
TrendEdge's proprietary AI model assigns ResMed a score of 6 out of 10, reflecting a moderately constructive but cautious outlook. A score at this level suggests the stock has identifiable positive fundamentals — namely its $27 billion market cap, established device portfolio, and SaaS segment momentum — but faces counterbalancing headwinds that temper conviction. The recent single-session price decline of 2.2% on above-average volume is a signal the AI model weighs carefully, as it may indicate institutional distribution or broader sector rotation rather than isolated noise. Social sentiment data remains sparse, with only six Reddit mentions in the past seven days and no directional sentiment recorded.
Looking ahead through 2026, key catalysts for ResMed include adoption trends in connected CPAP devices, expansion of its cloud-based patient management software, and any shifts in GLP-1 drug penetration among sleep apnea patients — a widely debated risk to long-term device demand. Regulatory developments and reimbursement policy changes in major markets also warrant close monitoring. The current AI score of 6/10 implies a hold posture with selective entry points worth tracking.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
2,881,283
Twitter Followers
10,885
Instagram Followers
17,206
YouTube Subscribers
60,000
LinkedIn Followers
259,357
Job Postings
269
LinkedIn Employees
9,016
News Mentions
0
Key Metrics